254 related articles for article (PubMed ID: 38504984)
21. Protein Tyrosine Phosphatase Non-Receptor 11 (
Richards CE; Elamin YY; Carr A; Gately K; Rafee S; Cremona M; Hanrahan E; Smyth R; Ryan D; Morgan RK; Kennedy S; Hudson L; Fay J; O'Byrne K; Hennessy BT; Toomey S
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445722
[No Abstract] [Full Text] [Related]
22. Early Combined SHP2 Targeting Reverses the Therapeutic Resistance of Vemurafenib in Thyroid Cancer.
Ma W; Tian M; Hu L; Ruan X; Zhang W; Zheng X; Gao M
J Cancer; 2023; 14(9):1592-1604. PubMed ID: 37325052
[TBL] [Abstract][Full Text] [Related]
23. SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy.
Drilon A; Sharma MR; Johnson ML; Yap TA; Gadgeel S; Nepert D; Feng G; Reddy MB; Harney AS; Elsayed M; Cook AW; Wong CE; Hinklin RJ; Jiang Y; Brown EN; Neitzel NA; Laird ER; Wu WI; Singh A; Wei P; Ching KA; Gaudino JJ; Lee PA; Hartley DP; Rothenberg SM
Cancer Discov; 2023 Aug; 13(8):1789-1801. PubMed ID: 37269335
[TBL] [Abstract][Full Text] [Related]
24. Deletion of the tyrosine phosphatase Shp2 in cervical cancer cells promotes reprogramming of glutamine metabolism.
Gao X; Kang J; Li X; Chen C; Luo D
FASEB J; 2023 Apr; 37(4):e22880. PubMed ID: 36943407
[TBL] [Abstract][Full Text] [Related]
25. Genome-wide CRISPR/Cas9 screens reveal shared and cell-specific mechanisms of resistance to SHP2 inhibition.
Wei W; Geer MJ; Guo X; Dolgalev I; Sanjana NE; Neel BG
J Exp Med; 2023 May; 220(5):. PubMed ID: 36820830
[TBL] [Abstract][Full Text] [Related]
26. Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma.
Mulero-Sánchez A; Ramirez CFA; du Chatinier A; Wang H; Koomen SJI; Song JY; de Groot MHP; Lieftink C; Bosma A; Burylo A; van Tellingen O; Beijersbergen RL; Wang C; Akkari L; Bernards R; Mainardi S
Mol Oncol; 2023 Jun; 17(6):964-980. PubMed ID: 36650715
[TBL] [Abstract][Full Text] [Related]
27. SHP2 deneddylation mediates tumor immunosuppression in colon cancer via the CD47/SIRPα axis.
Li Y; Zhou H; Liu P; Lv D; Shi Y; Tang B; Xu J; Zhong T; Xu W; Zhang J; Zhou J; Ying K; Zhao Y; Sun Y; Jiang Z; Cheng H; Zhang X; Ke Y
J Clin Invest; 2023 Feb; 133(4):. PubMed ID: 36626230
[TBL] [Abstract][Full Text] [Related]
28. SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses.
Christofides A; Katopodi XL; Cao C; Karagkouni D; Aliazis K; Yenyuwadee S; Aksoylar HI; Pal R; Mahmoud MAA; Strauss L; Tijaro-Ovalle NM; Boon L; Asara J; Vlachos IS; Patsoukis N; Boussiotis VA
Nat Immunol; 2023 Jan; 24(1):55-68. PubMed ID: 36581713
[TBL] [Abstract][Full Text] [Related]
29. SHP2 inhibition mitigates adaptive resistance to MEK inhibitors in KRAS-mutant gastric cancer through the suppression of KSR1 activity.
Zheng W; Yang Z; Song P; Sun Y; Liu P; Yue L; Lv K; Wang X; Shen Y; Si J; Zhang X; Ke Y; Cheng H; Hu W
Cancer Lett; 2023 Feb; 555():216029. PubMed ID: 36493900
[TBL] [Abstract][Full Text] [Related]
30. Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer.
Frank KJ; Mulero-Sánchez A; Berninger A; Ruiz-Cañas L; Bosma A; Görgülü K; Wu N; Diakopoulos KN; Kaya-Aksoy E; Ruess DA; Kabacaoğlu D; Schmidt F; Kohlmann L; van Tellingen O; Thijssen B; van de Ven M; Proost N; Kossatz S; Weber WA; Sainz B; Bernards R; Algül H; Lesina M; Mainardi S
Cell Rep Med; 2022 Nov; 3(11):100815. PubMed ID: 36384095
[TBL] [Abstract][Full Text] [Related]
31. Elaiophylin triggers paraptosis and preferentially kills ovarian cancer drug-resistant cells by inducing MAPK hyperactivation.
Li GN; Zhao XJ; Wang Z; Luo MS; Shi SN; Yan DM; Li HY; Liu JH; Yang Y; Tan JH; Zhang ZY; Chen RQ; Lai HL; Huang XY; Zhou JF; Ma D; Fang Y; Gao QL
Signal Transduct Target Ther; 2022 Sep; 7(1):317. PubMed ID: 36097006
[TBL] [Abstract][Full Text] [Related]
32. SHP2 regulates adipose maintenance and adipocyte-pancreatic cancer cell crosstalk via PDHA1.
Olou AA; Ambrose J; Jack JL; Walsh M; Ruckert MT; Eades AE; Bye BA; Dandawate P; VanSaun MN
J Cell Commun Signal; 2023 Sep; 17(3):575-590. PubMed ID: 36074246
[TBL] [Abstract][Full Text] [Related]
33. Protein Tyrosine Phosphatase SHP2 Controls Interleukin-8 Expression in Breast Cancer Cells.
Amante RJ; Auf der Maur P; Richina V; Sethi A; Iesmantavicius V; Bonenfant D; Aceto N; Bentires-Alj M
J Mammary Gland Biol Neoplasia; 2022 Jun; 27(2):145-153. PubMed ID: 35739379
[TBL] [Abstract][Full Text] [Related]
34. Pharmaceutical SH2 domain-containing protein tyrosine phosphatase 2 inhibition suppresses primary and metastasized liver tumors by provoking hepatic innate immunity.
Liu JJ; Xin B; Du L; Chen L; Long Y; Feng GS
Hepatology; 2023 May; 77(5):1512-1526. PubMed ID: 35503714
[TBL] [Abstract][Full Text] [Related]
35. Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer.
Chen X; Shu C; Li W; Hou Q; Luo G; Yang K; Wu X
J Med Chem; 2022 May; 65(9):6729-6747. PubMed ID: 35447031
[TBL] [Abstract][Full Text] [Related]
36. Targeting SHP2 phosphatase in breast cancer overcomes RTK-mediated resistance to PI3K inhibitors.
Heynen GJJE; Lisek K; Vogel R; Wulf-Goldenberg A; Alcaniz J; Montaudon E; Marangoni E; Birchmeier W
Breast Cancer Res; 2022 Apr; 24(1):23. PubMed ID: 35365185
[TBL] [Abstract][Full Text] [Related]
37. Targeting SHP2 sensitizes differentiated thyroid carcinoma to the MEK inhibitor.
Zhi J; Yi J; Hou X; Wang W; Yang W; Hu L; Huang J; Guo S; Ruan X; Gao M; Zheng X
Am J Cancer Res; 2022; 12(1):247-264. PubMed ID: 35141016
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of SHP2 (PTPN11) expression in solid tumors: A meta-analysis.
Zhou J; Guo H; Zhang Y; Liu H; Dou Q
PLoS One; 2022; 17(1):e0262931. PubMed ID: 35061863
[TBL] [Abstract][Full Text] [Related]
39. Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer.
Cruz-Duarte R; Rebelo de Almeida C; Negrão M; Fernandes A; Borralho P; Sobral D; Gallego-Paez LM; Machado D; Gramaça J; Vílchez J; Xavier AT; Ferreira MG; Miranda AR; Mansinho H; Brito MJ; Pacheco TR; Abreu C; Lucia-Costa A; Mansinho A; Fior R; Costa L; Martins M
Clin Cancer Res; 2022 Mar; 28(6):1203-1216. PubMed ID: 34980600
[TBL] [Abstract][Full Text] [Related]
40. Single-cell transcriptomics reveals opposing roles of Shp2 in Myc-driven liver tumor cells and microenvironment.
Chen WS; Liang Y; Zong M; Liu JJ; Kaneko K; Hanley KL; Zhang K; Feng GS
Cell Rep; 2021 Nov; 37(6):109974. PubMed ID: 34758313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
